Sugi Predict

Sugi Predict / Compounds / SCHEMBL2910862

SCHEMBL2910862

SCHEMBL2910862

c1ccc2c(C3CCCCC3)c[nH]c2c1

nearest known ligand 0.72

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 5/20 0.72
▸ ADRB2 P07550 1/20 0.72
▸ ADRA1D P25100 4/20 0.62
▸ KDM4E B2RXH2 2/20 0.58
▸ ATM Q13315 1/20 0.58
▸ BRD4 O60885 1/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ POLB P06746 1/20 0.57
▸ CREBBP Q92793 1/20 0.57
▸ HTR2A P28223 3/20 0.54
▸ HTR2B P41595 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL807343 0.98 HTR2C (0.74) HTR2CADRB2ADRA1DKDM4EATM
SCHEMBL28594057 0.94 HTR2C (0.74) HTR2CADRB2ADRA1DKDM4EATM
SCHEMBL734917 0.90 HTR2C (0.79) HTR2CADRB2ADRA1DKDM4EATM
SCHEMBL373923 0.84 HTR2C (1.00) HTR2CADRB2ADRA1DKDM4EATM
SCHEMBL29502102 0.84 HTR2C (1.00) HTR2CADRB2ADRA1DKDM4EATM
SCHEMBL6637446 0.84 HTR2C (0.70) HTR2CADRB2ADRA1DKDM4EATM
Hydrochloric Acid SCHEMBL31285949 0.82 HTR2C (1.00) HTR2CADRB2ADRA1DKDM4EATM
SCHEMBL1601125 0.82 HTR2C (0.68) HTR2CADRB2ADRA1DKDM4EATM
Methane SCHEMBL10788775 0.82 HTR2C (0.97) HTR2CADRB2ADRA1DKDM4EATM
SCHEMBL27779740 0.82 HTR2C (0.68) HTR2CADRB2ADRA1DKDM4EATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114014859-A Triazole indolol compound and synthesis method thereof 绍兴文理学院 2022-02-08 — — CN claimed
EP-2220074-A1 3,5-SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY Neuraxon, INC. (CA) 2010-08-25 — — EP claimed
WO-2009062318-A1 3,5-SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY NEURAXON, INC. (CA) 2009-05-22 — — WO claimed
US-20090131503-A1 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY NEURAXON, INC (CA) 2009-05-21 — — US claimed
CN-112742483-B Catalyst system for ethylene selective oligomerization and preparation and application thereof 华东理工大学 2024-04-02 — — CN disclosed
CN-114014859-A Triazole indolol compound and synthesis method thereof 绍兴文理学院 2022-02-08 — — CN disclosed
CN-112742483-A Catalyst system for selective oligomerization of ethylene, preparation and application thereof 华东理工大学 2021-05-04 — — CN disclosed
CN-108101830-B A kind of 3- replaces the preparation method of Oxoindole and derivative 中国科学院成都生物研究所 2019-08-23 — — CN disclosed
CN-105153011-B A kind of synthetic method of 2- sulfimides indoline 常州大学 2018-06-26 — — CN disclosed
US-9931347-B2 Pharmaceutical compound IOMET PHARMA LTD. (US) 2018-04-03 — — US disclosed
WO-2017023894-A1 MTHFD2 INHIBITORS AND USES THEREOF RAZE THERAPEUTICS, INC. (US) 2017-02-09 — — WO disclosed
US-20160367564-A1 Pharmaceutical Compound IOMET PHARMA LTD. (GB) 2016-12-22 — — US disclosed
US-20140303144-A1 COMPOUNDS AND METHODS OF TREATING HYPERTENSION MEDIVATION TECHNOLOGIES, INC. (US) 2014-10-09 — — US disclosed
US-20140228353-A1 COMPOUNDS AND METHODS OF TREATING DIABETES MEDIVATION TECHNOLOGIES, INC. (US) 2014-08-14 — — US disclosed
US-20130210803-A1 FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. 2013-08-15 — — US disclosed
US-7105516-B2 Compounds for the treatment of premature ejaculation BRISTOL-MYERS SQUIBB COMPANY (US) 2006-09-12 — — US disclosed
WO-2004026237-A2 COMPOUNDS FOR THE TREATMENT OF PREMATURE EJACULATION BRISTOL-MYERS SQUIBB COMPANY (US) 2004-04-01 — — WO disclosed
US-20040063768-A1 Compounds for the treatment of premature ejaculation BRISTOL-MYERS SQUIBB COMPANY 2004-04-01 — — US disclosed
US-5643922-A Indole cyclohexyl platelet activating factor antagonists ABBOTT LABORATORIES (US) 1997-07-01 — — US disclosed
US-5643922-A Indole cyclohexyl platelet activating factor antagonists ABBOTT LABORATORIES (US) 1997-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063768-A1 Compounds for the treatment of premature ejaculation HTR5A, SLC18A2, CYP17A1 HTR2C 55/4885ADRB2 402/4885ADRA1D 129/4885
US-20090131503-A1 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY SLC6A2, AANAT, NOS3 HTR2C 78/4885ADRB2 30/4885ADRA1D 76/4885
US-20160367564-A1 Pharmaceutical Compound TDO2, IDO1, IDO2 HTR2C 133/4885ADRB2 795/4885ADRA1D 1141/4885
US-20140303144-A1 COMPOUNDS AND METHODS OF TREATING HYPERTENSION ADRB2, ADRA2B, ADRA2C HTR2C 8/4885ADRB2 1/4885ADRA1D 26/4885
US-20140228353-A1 COMPOUNDS AND METHODS OF TREATING DIABETES ADRB2, ADRA2B, ADRA2C HTR2C 8/4885ADRB2 1/4885ADRA1D 20/4885
US-20130210803-A1 FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE HTR4, HTR3B, HTR2C HTR2C 3/4885ADRB2 334/4885ADRA1D 371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.